Effect of sirolimus on connective tissue disease relatedrefractory thrombocytopenia: clinical efficacyand immunomodulatory mechanism
Sirolimus is an effective and safe treatment option for CTD-RTP patients, and its effect may be related to its ability to increase the level of regulatory T cells in peripheral blood.
Authors
- Qian Liao (ORCID: https://orcid.org/0009-0009-0693-1563)
- Wanling Sun (ORCID: https://orcid.org/0000-0001-9429-3024)
- Xuemei Li (ORCID: https://orcid.org/0009-0008-8978-7757)
- Zhen Tian (ORCID: https://orcid.org/0000-0002-2677-9388)
- Li Su (ORCID: https://orcid.org/0000-0002-1775-1543)
- Xia Li (ORCID: https://orcid.org/0000-0002-7623-0019)
- Yi Zhao (ORCID: https://orcid.org/0000-0001-5619-8966)
- Xuejing Sun
Institutions
- Capital Medical University (CN)
Publication Details
- Journal
- Advances in Dermatology and Allergology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/ada.2025.155194
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00